U.S. market Closed. Opens in 11 hours 59 minutes

ABCL | AbCellera Biologics Inc. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Revenue38.02M485.42M375.20M233.16M11.61M8.83M
Cost of Revenue30.89M66.44M45.52M27.14M10.11MN/A
Gross Profit7.13M418.99M329.69M206.01M1.50M8.83M
Operating Expenses261.08M191.92M107.79M41.66M13.95M7.99M
Selling, General & Admin75.18M66.75M48.76M15.75M4.01M2.86M
Research & Development175.66M107.88M62.06M29.39M10.11M5.80M
Other Operating Expenses6.78M17.29M-3.04M-3.48M-170.41K-675.51K
Operating Income-237.21M216.51M204.41M156.03M-4.12M-753.00K
Other Expenses / Income6.78M22.59M14.74M1.80M1.91M-362.00K
Before Tax Income-174.03M239.10M219.15M157.83M-2.21M309.00K
Income Tax Expenses-27.63M80.58M65.69M38.91M209.20K1.27M
Net Income-146.40M158.52M153.46M118.92M-2.42M309.00K
Interest ExpensesN/A4.04M5.22M6.51M209.20K212.00K
Basic Shares Outstanding289.17M285.06M275.76M269.50M154.09M215.41M
Diluted Shares Outstanding289.17M314.83M318.29M269.50M154.09M237.72M
EBITDA-192.16M276.25M242.48M169.91M-340.67K1.80M
EBITDA Margin-505.35%56.91%64.63%72.88%-2.93%20.39%
EBIT-174.03M243.14M224.37M164.34M-2.00M1.80M
EBIT Margin-457.67%50.09%59.80%70.49%-17.24%20.33%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙